Immunotherapy is revolutionising the outcomes for patients with advanced-stage melanoma. Indeed, the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody ipilimumab was the first agent in living memory to provide a survival benefit for these patients in the setting of a randomized trial 1 . Progress in adjuvant therapy for patients with high-risk melanoma has lagged behind that made in advancedstage disease; until 2016, high-dose interferon (HDI) was the only therapy associated with a survival benefit, although consensus on the benefits of this treatment is lacking 2 . This treatment landscape has now changed. In the European Organisation for Research and Treatment of Cancer (EORTC) 18071 study 3 , patients with fully resected stage III cutaneous melanoma were randomly assigned to receive either ipilimumab 10 mg/kg or placebo. The results of this trial, published in 2016, revealed a clear overall survival benefit at 5 years of 11% (65% versus 54%; hazard ratio (HR) 0.72; 95% confidence interval (CI) 0.58-0.88; P = 0.001) 3 . The incidence of toxicities was higher in the ipilimumab group compared with placebo, with 54% versus 26% of patients experiencing grade 3-4 adverse events (AEs), and 42% versus 3% having immune-related adverse events (irAE). Of note, five patients in the ipilimumab group (1%) died owing to treatment-related complications. Adjuvant ipilimumab therapy was approved in the USA in October 2015 for this indication, owing to this trial meeting the relevant differences in global health-status scores (defined by the authors as a difference of ≥10 points) observed during or after induction therapy. Clinically relevant deterioration was observed at week 10 for some symptoms, but after induction treatment was completed, no clinically relevant differences remained. How can this conclusion be correct for a treatment that was discontinued in one-half of the patients owing to drug-related AEs, when the median number of treatments received was four (and 12 weeks in duration), and when only 42% of patients subsequently received one or more maintenance treatments?
The timing of the assessments might have contributed to the results. Each assessment related only to the preceding 7 days, and the last assessment during the induction phase was at week 10, at the time of administration of the fourth cycle of treatment -no further questionnaires were collected until week 24. The median time to onset of grade 2-5 irAEs, however, ranged from 4-12 weeks, and the median time to resolution was 4-8 weeks 5 . Therefore, the results of the QoL questionnaires might not have identified all patients with symptoms. Furthermore, the consistently lower questionnaire-completion rates among ipilimumab-treated patients compared with placebo-treated patients (80% versus 92% at week 10) is a particular concern, and it seems surprising that the authors found no evidence that this difference was related to AE-related patient dropout, given that both toxicity primary progression-free-survival end point, but has yet to be submitted for approval in the EU. Substantial concern remains regarding the toxicity of this regimen, considering that almost 50% of patients will have been cured by surgery alone 3, 4 . The recent publication of quality-of-life (QoL)-related data from the EORTC 18071 study would, at first sight, seem to provide some reassurance about the tolerability of adjuvant ipilimumab 5 . The authors report that health-related QoL, as measured using the EORTC QLQ-C30 questionnaire, was similar between groups, with no clinically I M M U N OT H E R A P Y Does adjuvant ipilimumab have little adverse effect on quality of life?
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and attrition rates were far higher among ipilimumab-treated patients 5 . One could deduce that the small proportion of patients who remained on treatment and completed the QoL questionnaires were systematically different to their counterparts in the placebo group, and so this is not a like-for-like comparison.
In addition, whether differences of ≥10 points or more in QoL scores are clinically meaningful in today's treatment landscape remains to be determined. This cut-off value was set two decades ago, long before the QoL effects of irAEs could be taken into account, and the use of this cut-off raises the question of whether a new instrument is needed to reliably capture the QoL of patients receiving immunotherapy. Fatigue and insomnia were not specifically addressed in the original report because they are not irAEs 5 , but these were two of the three symptoms for which a patent deterioration was observed in the symptom-specific scores of ipilimumab-treated patients. Insomnia is an unexpected toxicity, rarely reported in clinical trials, and is almost certainly related to the use of corticosteroids to manage immunological toxicities 6 . This observation highlights the importance of reporting all toxicities experienced, rather than focusing on specific items of special interest related to the mechanism of action of a drug. Importantly, chronic low-grade fatigue is likely to have a much more marked effect on QoL than, for example, a transient, asymptomatic grade 3 rise in hepatic transaminases. Finally, even if we accept the precise 10-point difference as the threshold of clinical relevance, then the 95% CIs around the mean global health-score at 10 weeks show the data are compatible with a ≥10-point difference in QoL between the treated and placebo groups. This difficulty raises further concern about the conclusion of limited impairment in QoL in ipilimumab-treated patients, despite more-frequent investigator-reported grade 3-4 AEs, compared with placebo-treated patients.
Of note, the QoL-related conclusions from EORTC 18071 paint a very different picture to the results of the ECOG 1697 study that assessed 4-weeks induction with adjuvant IFNα-2b in patients with intermediate-risk melanoma 7 . In the latter study 7 , the 5-year overall survival was 83% for both the observation and the IFNα-2b arms (P = 0.558). However, the rate of treatment-related grade ≥3 AEs was 4.6% and 57.9% for the observation and IFNα-2b groups, respectively (P <0.001); the QOL measures of the 'Main Activity, Daily Living, Health, and Patient Score' were significantly different between the two treatment arms at day 22 (each comparison with P <0.001) 7 . While direct comparison of the results of these trials is complicated because the toxicity profile of HDI is not the same as that of ipilimumab and QoL was not assessed in the same way, many clinicians with experience of both treatments will be surprised by the different outcomes.
Where can we go from here? Three main questions are being addressed in clinical trials, many of which have completed accrual (TABLE 1) . First, whether the benefit for patients treated with 3 mg/kg ipilimumab (the approved dose for patients with advanced-stage disease) will be similar to that associated with the 10 mg/kg dose (the highest dose tested in the EORTC study), but with less toxicity. Second, how do outcomes of adjuvant ipilimumab and adjuvant HDI therapy compare. Finally, whether newly developed PD-1-checkpoint inhibitors (such as nivolumab and pembrolizumab) are active as adjuvant therapy. Results of most of these studies will be reported in the next 2 to 3 years.
In conclusion, adjuvant ipilimumab has demonstrated a clear survival benefit for patients with advanced-stage melanoma, and the investigators involved in EORTC 18071 are to be congratulated for having assessed QoL in these patients. However, considerable concerns remain regarding the tolerability of this regimen, and how best to assess this aspect of treatment. Thus, we would urge caution in interpreting these QoL data in an overly positive way.
